Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On January 25, 2016, OncoMed issued a statement regarding the Company’s Phase 2 ALPINE clinical trial for the pancreatic cancer treatment Tarextumab. According to a Company press release, an independent data safety monitoring board (or DSMB) has determined the study illustrates a “low likelihood of a statistically significant benefit in overall survival.” Upon this news, shares of OncoMed were down more than 44% on intraday trading on January 25, 2016. To obtain additional information, go to:

http://zlk.9nl.com/oncomed-omed

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.